Arcutis Biotherapeutics (ARQT) Accumulated Expenses: 2020-2025
Historic Accumulated Expenses for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $93.0 million.
- Arcutis Biotherapeutics' Accumulated Expenses rose 76.12% to $93.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.0 million, marking a year-over-year increase of 76.12%. This contributed to the annual value of $66.8 million for FY2024, which is 96.79% up from last year.
- According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Accumulated Expenses is $93.0 million, which was up 5.83% from $87.9 million recorded in Q2 2025.
- Over the past 5 years, Arcutis Biotherapeutics' Accumulated Expenses peaked at $93.0 million during Q3 2025, and registered a low of $10.6 million during Q2 2021.
- Over the past 3 years, Arcutis Biotherapeutics' median Accumulated Expenses value was $42.6 million (recorded in 2024), while the average stood at $49.7 million.
- Per our database at Business Quant, Arcutis Biotherapeutics' Accumulated Expenses fell by 13.69% in 2021 and then surged by 126.67% in 2024.
- Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Accumulated Expenses stood at $25.5 million in 2021, then grew by 10.90% to $28.3 million in 2022, then climbed by 19.84% to $33.9 million in 2023, then skyrocketed by 96.79% to $66.8 million in 2024, then skyrocketed by 76.12% to $93.0 million in 2025.
- Its Accumulated Expenses was $93.0 million in Q3 2025, compared to $87.9 million in Q2 2025 and $65.8 million in Q1 2025.